EXEL icon

Exelixis

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 59.6%
Negative

Negative
The Motley Fool
yesterday
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to be extremely risky clinical-stage biotechs that may no longer exist in five years.
The Ultimate Biotech Stock to Buy With $50 Right Now
Positive
Zacks Investment Research
6 days ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
7 days ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Positive
The Motley Fool
15 days ago
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Neutral
Seeking Alpha
21 days ago
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Neutral
Seeking Alpha
1 month ago
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 8:00 AM EDT Company Participants Christopher Senner - Executive VP & CFO Andrew Peters - Senior Vice President of Strategy Conference Call Participants Robert Burns - H.C.
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Neutral
Seeking Alpha
1 month ago
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm.
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Positive
Zacks Investment Research
1 month ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock